Home » BMS’ Opdivo-Yervoy Treatment for Head and Neck Cancer Falters in Phase 3 Trial
BMS’ Opdivo-Yervoy Treatment for Head and Neck Cancer Falters in Phase 3 Trial
Bristol Myers Squibb’s (BMS) Opdivo (nivolumab)-Yervoy (ipilimumab) combination did not significantly improve overall survival for head and neck cancer patients in a late-stage trial.
The phase 3 study compared the Opdivo-Yervoy combination against a chemotherapy regimen (cetuximab, cisplatin/carboplatin and fluorouracil) as a first-line therapy for patients with recurrent or metastatic squamous cell carcinoma.
Despite the disappointing results, BMS still sees strong potential for Opdivo-Yervoy for other indications, noting that the combination significantly improved survival in six phase 3 trials for five other cancers.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May